StreetInsider.com News Articles

SELLAS Life Sciences Group, Inc. (SLS) Reports In-Line Q2 EPS

Tue, 11 Aug 2026 16:36:11 -0400

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05).

For earnings history and earnings-related data on SELLAS Life Sciences Group, Inc. (SLS) click here.

Form 8-K SELLAS Life Sciences For: Aug 11

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905708.html

Form 8-K SELLAS Life Sciences For: Aug 11

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905708.html

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 16:05:00 -0400

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event -

- 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 -

- Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing -

- $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 -

NEW YORK, Aug.

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 16:05:00 -0400

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event -

- 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 -

- Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing -

- $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 -

NEW YORK, Aug.

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 16:05:00 -0400

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event -

- 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 -

- Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing -

- $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 -

NEW YORK, Aug.

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 16:05:00 -0400

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event -

- 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 -

- Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing -

- $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 -

NEW YORK, Aug.

Form 10-Q SELLAS Life Sciences For: Jun 30

Tue, 11 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260811/26905439.html

Form 10-Q SELLAS Life Sciences For: Jun 30

Tue, 11 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260811/26905439.html

Form SCHEDULE 13G SELLAS Life Sciences Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:58:00 -0400

si-local-file:///var/storage/secattach/20260807/26889206.html

Form SCHEDULE 13G SELLAS Life Sciences Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:58:00 -0400

si-local-file:///var/storage/secattach/20260807/26889206.html

Ecuador's Mining Reset Is Opening Doors. Salazar Resources Is Walking Through All of Them